Aggregate evidence quality: D; expert opinion and reasoning from first principles. . | |
---|---|
Benefit | Prevention of complications, administration of effective therapy. |
Harm | Adverse effects of secondary antibiotic therapy. |
Cost | Direct cost of medications, often substantial for second-line agents. |
Benefits-harm assessment | Preponderance of benefit. |
Value judgments | Clinician must determine whether cost and adverse effects associated with change in antibiotic is justified given the severity of illness. |
Role of patient preferences | Limited in patients whose symptoms are severe or worsening, but caregivers of mildly affected children who are failing to improve may reasonably defer change in antibiotic. |
Intentional vagueness | None. |
Exclusions | None. |
Strength | Option. |
Aggregate evidence quality: D; expert opinion and reasoning from first principles. . | |
---|---|
Benefit | Prevention of complications, administration of effective therapy. |
Harm | Adverse effects of secondary antibiotic therapy. |
Cost | Direct cost of medications, often substantial for second-line agents. |
Benefits-harm assessment | Preponderance of benefit. |
Value judgments | Clinician must determine whether cost and adverse effects associated with change in antibiotic is justified given the severity of illness. |
Role of patient preferences | Limited in patients whose symptoms are severe or worsening, but caregivers of mildly affected children who are failing to improve may reasonably defer change in antibiotic. |
Intentional vagueness | None. |
Exclusions | None. |
Strength | Option. |